Hepatic arterial infusion pump (HAIP) chemotherapy delivers targeted therapy directly to the liver, markedly improving survival outcomes in liver-confined colorectal metastases (CRLM) and intrahepatic cholangiocarcinoma (ICCA). In unresectable CRLM, five-year overall survival rates reach 50%. Adjuvant HAIP after tumor resection shows two-year survival of 86%, compared to 72% with systemic therapy alone. ICCA patients benefit similarly, with response rates up to 58% and three-year overall survival as high as 43%.
Review by Outmani L, Rousian M (…) Gholami S et 5 al. in Ann Surg Oncol
© 2025. Society of Surgical Oncology.